Pharma BD Deal Intelligence
A next-generation oral SYK inhibitor licensing deal that gave Agios global rights to cevidoplenib for just $25 million upfront, targeting immune thrombocytopenia. Oscotec retains South Korea commercialization rights post-Phase 3, but the modest $165 million total deal value signals limited near-term conviction.
Agios Licenses Cevidoplenib in $165M SYK Deal. Agios Pharmaceuticals secured an exclusive global license to cevidoplenib from South Korea's Oscotec for a…
Agios Enters Global License Agreement For Cevidoplenib. Agios Pharmaceuticals entered an exclusive global license agreement with Oscotec to develop and…
Eyes on Asia: Olix, Agios, Eli Lilly. Agios licensed global rights to cevidoplenib from South Korea's Oscotec for up to $165 million, targeting immune…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
On June 1, 2026, Agios Pharmaceuticals entered an exclusive global license agreement with South Korea's Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK (spleen tyrosine kinase) inhibitor, with an initial focus on immune thrombocytopenia (ITP), a rare autoimmune bleeding disorder. Oscotec receives $25 million upfront and is eligible for up to $140 million in development and regulatory milestones across up to three indications in the U.S. and Europe, plus commercial milestones and tiered royalties ranging from high-single-digit to mid-teen percentages on net sales. Oscotec retains an option to commercialize cevidoplenib in South Korea following Phase 3 results.
20K US cases/yr
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder in which antiplatelet autoantibodies and T-cell-mediated destruction reduce platelet counts, causing bleeding risk. Chronic ITP predominates in adults; standard therapies include corticosteroids, TPO receptor agonists, rituximab and the SYK inhibitor fostamatinib.
Cevidoplenib is an oral next-generation SYK inhibitor. Its 60-patient Phase 2 in chronic/persistent ITP (NCT04056195) missed the primary platelet-response endpoint on statistical significance but showed durable, clinically meaningful secondary platelet responses vs placebo; further development is planned.
Agios entered an exclusive global license to develop and commercialize Oscotec's cevidoplenib, an oral next-generation SYK inhibitor, initially for immune thrombocytopenia (ITP). Oscotec receives $25M upfront and up to $140M in development/regulatory milestones across up to three indications plus commercial milestones and high-single-digit to mid-teen royalties; Oscotec retains a South Korea option after Phase 3.
Transaction between Agios Pharmaceuticals and Oscotec is pending completion. Assessment will be updated upon deal close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Agios Pharmaceuticals Inc. / Oscotec Inc. (this deal) | 2026 | $165M | 63 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2026 deals · Hematology deals